 HomeProductsAPIs And IntermediatesAPIs PowderAnti-cancer API Brigatinib cas 1197953-54-0

Contact Supplier

Ms. Lily

Leave a message

Contact Now

Anti-cancer API Brigatinib cas 1197953-54-0

$5

≥1
Bag/Bags

Payment Type:

L/C,T/T

Incoterm:

FOB,CFR,CIF

Min. Order:

1 Bag/Bags

Transportation:

Ocean,Air

Port:

Shanghai

Contact Now

Product Description

Product Attributes
Supply Ability & Additional Information
Packaging & Delivery

< >

Overview

Product Attributes

Model No.: cas 1197953-54-0

Brand: DM

Grade Standard: Medicine Grade

Supply Ability & Additional Information

Packaging: double PE with aluminium foil bag

Productivity: 100kg/month

Transportation: Ocean,Air

Place of Origin: Hebei,China

Supply Ability: 100kg/month

Certificate: ISO9001

Port: Shanghai

Payment Type: L/C,T/T

Incoterm: FOB,CFR,CIF

Packaging & Delivery

Selling Units:: Bag/Bags

Package Type:: double PE with aluminium foil bag

Picture Example:

Brigatinib potently inhibits the in vitro kinase activity of ALK (IC50, 0.6 nM) and all five mutant variants tested, including G1202R (IC50, 0.6-6.6 nM). Brigatinib demonstrates a high degree of selectivity, only inhibiting 11 additional native or mutant kinases with IC50 <10 nM. These include ROS1, FLT3, and mutant variants of FLT3 (D835Y) and EGFR (L858R; IC50, 1.5-2.1 nM). Brigatinib exhibits more modest activity against EGFR with a T790M resistance mutation (L858R/T790M), native EGFR, IGF1R, and INSR (IC50, 29-160 nM) and does not inhibit MET (IC50 >1000 nM). In cellular assays, brigatinib inhibits ALK and ROS1 with IC50s of 14 and 18 nM, respectively. Brigatinib inhibits FLT3 and IGF-1R with about 11-fold lower potency (IC50, 148-158 nM) and inhibits mutant variants of FLT3 and EGFR with 15- to 35-fold lower potency (IC50, 211-489 nM). Brigatinib inhibits cell growth with GI50 values ranging from 503 to 2,387 nM in three ALK-negative ALCL and NSCLC cell lines[1]. Brigatinib inhibits ALK activity and abrogates proliferation of ALK addicted neuroblastoma cell lines, with IC50 of 75.27 ± 8.89 nM. Brigatinib inhibits both the ALK-I1171N and the ALK-G1269A mutant receptors at 10 and 4 nM levels, respectively[3].

Product Categories : APIs And Intermediates > APIs Powder

Hot Products

Email to this supplier

*Subject:
*To:

Ms. Lily
*Email:
*Message:

Your message must be between 20-8000 characters